Medpace Holdings, Inc. (MEDP)

Market Cap	10.37B
Revenue (ttm)	2.11B
Net Income (ttm)	404.34M
Shares Out	30.47M
EPS (ttm)	12.63
PE Ratio	26.94
Forward PE	27.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	303,724
Open	346.09
Previous Close	344.85
Day's Range	339.44 - 350.00
52-Week Range	302.01 - 459.77
Beta	1.36
Analysts	Buy
Price Target	389.89 (+14.6%)
Earnings Date	Feb 10, 2025

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 5,900
• Stock Exchange: NASDAQ
• Ticker Symbol: MEDP
• Website: https://www.medpace.com

Financial Performance

In 2024, Medpace Holdings's revenue was $2.11 billion, an increase of 11.84% compared to the previous year's $1.89 billion. Earnings were $404.34 million, an increase of 43.07%.

Analyst Forecast

According to 10 analysts, the average rating for MEDP stock is "Buy." The 12-month stock price forecast is $389.89, which is an increase of 14.60% from the latest price.

Price Target

$389.89

(14.60% upside)

Analyst Consensus: Buy